Seeking a potential breakthrough therapy for patients with
Complex Regional Pain Syndrome Type 1 (CRPS-1)
Overview
Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need.
Our lead investigational program targets complex regional pain syndrome type 1 (CRPS-1), a devastating bone disease that causes severe, unrelenting and frequently lasting pain following trauma to the bone or an injury.
Patients may experience significant functional loss, sleep disturbance, and meaningful diminished quality of life and independence.
The Phase 3 pivotal trial (CRPS-RISE) represents a first-in-class approach to addressing a disease with no FDA-approved medicines.
What is Complex Regional Pain Syndrome Type 1?
Complex regional pain syndrome type 1 (CRPS-1) is a rare and debilitating condition following an injury or trauma to the bone. There are currently no FDA-approved medicines available to treat this high unmet need patient population.
Our Approach to CRPS-1 with Neridronate
Neridronate is a differentiated bisphosphonate with established efficacy in several bone disease, including in CRPS-1 patients. Its differentiated structure and unique binding characteristics allow for a balance of safety and efficacy compared to other bisphosphonates.
evaluating neridronate in patients with CRPS-1 in the United States
Loading...